Yong Sang Hong Selected Research

Pancreatic Neoplasms (Pancreatic Cancer)

12/2020	Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells.
4/2016	SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
9/2015	A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer.
5/2012	The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2.
1/2012	YM155 induces EGFR suppression in pancreatic cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yong Sang Hong Research Topics

Disease

70	Neoplasms (Cancer) 01/2024 - 08/2007
68	Colorectal Neoplasms (Colorectal Cancer) 03/2024 - 02/2009
31	Rectal Neoplasms (Rectal Cancer) 06/2022 - 08/2008
16	Colonic Neoplasms (Colon Cancer) 11/2022 - 02/2009
16	Neoplasm Metastasis (Metastasis) 07/2022 - 02/2009
8	Adenocarcinoma 01/2018 - 01/2011
5	Stomach Neoplasms (Stomach Cancer) 01/2024 - 11/2013
5	Neutropenia 11/2023 - 03/2011
5	Pancreatic Neoplasms (Pancreatic Cancer) 12/2020 - 01/2012
4	Nausea 11/2023 - 10/2010
4	Disease Progression 01/2023 - 11/2012
4	Microsatellite Instability 01/2022 - 09/2011
3	Vomiting 11/2023 - 10/2010
3	Diarrhea 04/2014 - 08/2007
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2023 - 01/2017
2	Necrosis 06/2022 - 04/2014
2	Melanoma (Melanoma, Malignant) 01/2021 - 12/2013
2	Hypothyroidism 01/2020 - 12/2019
2	Lymphatic Metastasis 01/2018 - 05/2011
2	Carcinogenesis 10/2016 - 06/2014
2	Lung Neoplasms (Lung Cancer) 04/2015 - 01/2012
2	Fatigue 10/2014 - 07/2010
2	Hand-Foot Syndrome 04/2014 - 08/2007
2	Proteinuria 02/2014 - 02/2013
2	Anorexia 11/2013 - 08/2007
2	Exanthema (Rash) 01/2013 - 10/2011
2	Pathologic Complete Response 01/2013 - 02/2009
1	Edema (Dropsy) 06/2022
1	Fibrosis (Cirrhosis) 06/2022
1	Desmoplastic Small Round Cell Tumor 01/2021

Drug/Important Bio-Agent (IBA)

28	Irinotecan (Camptosar)FDA LinkGeneric 12/2023 - 06/2009
25	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2022 - 06/2009
21	Cetuximab (Erbitux)FDA Link 01/2022 - 06/2009
19	Capecitabine (Xeloda)FDA Link 11/2021 - 08/2007
16	Fluorouracil (Carac)FDA LinkGeneric 12/2023 - 06/2008
10	Bevacizumab (Avastin)FDA Link 03/2024 - 07/2009
10	Leucovorin (Folinic Acid)FDA Link 12/2023 - 10/2011
8	Biomarkers (Surrogate Marker)IBA 01/2023 - 12/2009
7	ErbB Receptors (EGF Receptor)IBA 01/2016 - 06/2009
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2009
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 07/2009
4	Monoclonal AntibodiesIBA 01/2023 - 10/2011
4	Histone Deacetylase InhibitorsIBA 04/2016 - 12/2010
3	Carcinoembryonic AntigenIBA 01/2023 - 07/2009
3	Calcibiotic Root Canal SealerIBA 11/2022 - 01/2015
3	Phosphotransferases (Kinase)IBA 01/2021 - 07/2012
3	regorafenibIBA 01/2020 - 07/2019
3	Gemcitabine FDA Link 04/2016 - 01/2012
3	sepantroniumIBA 04/2015 - 01/2012
3	SurvivinIBA 04/2015 - 01/2012
3	Simvastatin (Zocor)FDA LinkGeneric 02/2015 - 09/2009
3	Paclitaxel (Taxol)FDA LinkGeneric 02/2015 - 10/2007
2	Tyrosine Kinase InhibitorsIBA 01/2024 - 12/2019
2	MucinsIBA 06/2022 - 01/2013
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2022
2	binimetinibIBA 01/2021 - 10/2019
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 10/2016
2	encorafenibIBA 01/2021 - 10/2019
2	Inhibitor of Apoptosis ProteinsIBA 12/2020 - 09/2015
2	Lapatinib (GW572016)FDA Link 12/2018 - 01/2014
2	Trastuzumab (Herceptin)FDA Link 12/2018 - 12/2014
2	Sunitinib (Sutent)FDA Link 01/2017 - 04/2014
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 11/2015 - 06/2014
2	Caspase 3 (Caspase-3)IBA 11/2015 - 05/2014
2	XELOXIBA 04/2012 - 01/2012
2	Cisplatin (Platino)FDA LinkGeneric 06/2008 - 08/2007
1	olaparibIBA 03/2024
1	Angiogenesis InhibitorsIBA 01/2024
1	apatinibIBA 01/2024
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2024
1	LutetiumIBA 12/2023
1	Peptide Receptors (Peptide Receptor)IBA 12/2023
1	Radioisotopes (Radionuclides)IBA 12/2023
1	Somatostatin Receptors (Somatostatin Receptor)IBA 12/2023
1	GC1118IBA 12/2023
1	Tumor Biomarkers (Tumor Markers)IBA 01/2023
1	Immune Checkpoint InhibitorsIBA 10/2022
1	B7-H1 AntigenIBA 10/2022
1	N-acetyltalosaminuronic acid (NAT)IBA 06/2022
1	Keratins (Keratin)IBA 05/2022
1	Neurofibromin 1 (Neurofibromin)IBA 01/2022
1	durvalumabIBA 01/2022
1	N- (4- (3- (1H- 1,2,4- triazol- 1- yl)- 4- (3,4,5- trimethoxybenzoyl)phenyl)thiazol- 2- yl)- 2- amino- 3- methylbutanamideIBA 10/2021
1	CaspasesIBA 12/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2020

Therapy/Procedure

54	Drug Therapy (Chemotherapy) 01/2023 - 08/2007
28	Therapeutics 03/2024 - 06/2009
23	Chemoradiotherapy 01/2022 - 08/2008
10	Adjuvant Chemotherapy 11/2023 - 07/2010
7	Radiotherapy 07/2022 - 08/2008
4	Combination Drug Therapy (Combination Chemotherapy) 04/2018 - 08/2007
3	Neoadjuvant Therapy 11/2019 - 07/2010
2	Drug Tapering 11/2023 - 01/2021
2	Precision Medicine 07/2023 - 01/2022
2	Radiofrequency Ablation 07/2022 - 07/2013
2	Salvage Therapy 11/2017 - 11/2010
2	Aftercare (After-Treatment) 11/2010 - 07/2009
2	Proctectomy 09/2010 - 07/2010
1	Robotic Surgical Procedures 06/2022
1	Palliative Care (Palliative Therapy) 01/2022